Case Study Corner: LNP Formulation

04.26.2023

Your biggest challenges inspire us. That's why Emergent supports innovative drug makers that make the seemingly impossible possible. In our latest blog series, Case Study Corner, discover how we've helped our clients overcome their biggest challenges during the development and manufacturing process.

Summary: A mid size biotech company partnered with Emergent to characterize a multi-step lipid nanoparticle formulation process for a Phase III mRNA-LNP vaccine.

20211111-EBSI_Gaithersburg-0047-of-0052_9538NIKON Z 7-RS

Emergent CDMO

Case Studies Development Services Nanoparticles

03.01.2022

Using Viruses to Target Cancer Cells

Innovation in cancer therapeutics is moving at an accelerated pace. Advancements in the development and manufacturing of...

11.19.2021

Finding the Right CDMO Partner for Tech Transfer

Regardless of where a drug candidate is in the development pipeline, performing a technology transfer (tech transfer) presents...

08.17.2022

How CDMOs Can Support Nanoparticles for Gene Therapy, Immuno-Oncology and Vaccines

Nanoparticles have experienced increasing demand in recent years in biopharmaceutical formulations, owing to their utility for...